STAT+: FDA discloses reasons for rejecting Summit drug
The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:
The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:
comments(0)
5-min edit window · permanent after that